CUE Stock — Cue Biopharma, Inc.

Cue Biopharma, Inc. (CUE)

Updated October 16, 2026.

CUE is a Stock. Total return is -95.2% over the past 8.8 years, 319.5 points behind SPY at 224.3%.

Cue Biopharma is a clinical-stage biopharmaceutical company developing immunological therapies, including CUE-221, an anti-IgE antibody in Phase 2 development for allergic diseases, and CUE-401, a bifunctional program advancing toward Phase 1 trials for autoimmune conditions, alongside its proprietary Immuno-STAT platform for targeted T-cell regulation. The company does not currently distribute dividends. Cue Biopharma appeals to investors seeking exposure to early-stage biotech development with no current income component, where returns depend on clinical progress and eventual commercialization or acquisition rather than regular payouts.

CUE performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.2% over the past 8.8 years, 319.5 points behind SPY at 224.3%. Over the past year its total return — price change plus distributions reinvested — is -29.5%. Its deepest 1-year drawdown was 78.5%.

CUE key facts

Asset type

Stock

Asset class

Equity

Inception date

01/02/2018

Distribution frequency

None

Last close

$16.71 (as of 2026-10-16)

Market cap

$121,388,358

Average volume

106462.0

Beta

2.628

Payout ratio

0.0%

EPS

$-29.59

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CUE risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 78.5%.

Who may consider CUE — and who may not

It is a weaker fit for investors who need monthly cash flow (CUE does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CUE

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions